Recent Updates
Recently added Catalysts
IMMP

Progress Towards Clinical Development of IMP761 – A LAG-3 Agonist Antibody

Monday, September 3, 2018 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Progress Towards Clinical Development of IMP761 – A LAG-3 Agonist Antibody

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Full Press Release Details

Progress Towards Clinical Development of IMP761 – A LAG-3 Agonist Antibody.
ShareAdd on Google
Tags: IMMP Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Sep 3, 2018

Biotech snapshot

Lead asset
eftilagimod alfaPhase 3
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) →

Catalyst track record

+76%
best trade around IMMP's most recent catalyst

Peak hindsight return over a 120-day window, across 13 tracked FDA/PDUFA catalysts for IMMP.

See every catalyst's timing & PoA →